These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 25869538

  • 1. Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates.
    Jones S, Grignard L, Nebie I, Chilongola J, Dodoo D, Sauerwein R, Theisen M, Roeffen W, Singh SK, Singh RK, Singh S, Kyei-Baafour E, Tetteh K, Drakeley C, Bousema T.
    J Infect; 2015 Jul; 71(1):117-27. PubMed ID: 25869538
    [Abstract] [Full Text] [Related]

  • 2. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania.
    Bousema T, Roeffen W, Meijerink H, Mwerinde H, Mwakalinga S, van Gemert GJ, van de Vegte-Bolmer M, Mosha F, Targett G, Riley EM, Sauerwein R, Drakeley C.
    PLoS One; 2010 Nov 29; 5(11):e14114. PubMed ID: 21124765
    [Abstract] [Full Text] [Related]

  • 3. Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmission.
    Ouédraogo AL, Roeffen W, Luty AJ, de Vlas SJ, Nebie I, Ilboudo-Sanogo E, Cuzin-Ouattara N, Teleen K, Tiono AB, Sirima SB, Verhave JP, Bousema T, Sauerwein R.
    Infect Immun; 2011 Dec 29; 79(12):4957-64. PubMed ID: 21969000
    [Abstract] [Full Text] [Related]

  • 4. Associations Between Helminth Infections, Plasmodium falciparum Parasite Carriage and Antibody Responses to Sexual and Asexual Stage Malarial Antigens.
    Ateba-Ngoa U, Jones S, Zinsou JF, Honkpehedji J, Adegnika AA, Agobe JC, Massinga-Loembe M, Mordmüller B, Bousema T, Yazdanbakhsh M.
    Am J Trop Med Hyg; 2016 Aug 03; 95(2):394-400. PubMed ID: 27273645
    [Abstract] [Full Text] [Related]

  • 5. Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum.
    Singh SK, Thrane S, Chourasia BK, Teelen K, Graumans W, Stoter R, van Gemert GJ, van de Vegte-Bolmer MG, Nielsen MA, Salanti A, Sander AF, Sauerwein RW, Jore MM, Theisen M.
    Front Immunol; 2019 Aug 03; 10():1256. PubMed ID: 31231386
    [Abstract] [Full Text] [Related]

  • 6. Dynamics of anti-MSP3 and Pfs230 antibody responses and multiplicity of infection in asymptomatic children from southern Ghana.
    Amoah LE, Acquah FK, Ayanful-Torgby R, Oppong A, Abankwa J, Obboh EK, Singh SK, Theisen M.
    Parasit Vectors; 2018 Jan 05; 11(1):13. PubMed ID: 29304870
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
    Baptista BO, de Souza ABL, Riccio EKP, Bianco-Junior C, Totino PRR, Martins da Silva JH, Theisen M, Singh SK, Amoah LE, Ribeiro-Alves M, Souza RM, Lima-Junior JC, Daniel-Ribeiro CT, Pratt-Riccio LR.
    Malar J; 2022 Jan 04; 21(1):6. PubMed ID: 34983540
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
    Theisen M, Jore MM, Sauerwein R.
    Expert Rev Vaccines; 2017 Apr 04; 16(4):329-336. PubMed ID: 28043178
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Datta D, Bansal GP, Gerloff DL, Ellefsen B, Hannaman D, Kumar N.
    Vaccine; 2017 Jan 05; 35(2):264-272. PubMed ID: 27912985
    [Abstract] [Full Text] [Related]

  • 18. Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe.
    Paul NH, Vengesai A, Mduluza T, Chipeta J, Midzi N, Bansal GP, Kumar N.
    Acta Trop; 2016 Nov 05; 163():103-8. PubMed ID: 27491342
    [Abstract] [Full Text] [Related]

  • 19. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK, Thrane S, Janitzek CM, Nielsen MA, Theander TG, Theisen M, Salanti A, Sander AF.
    Vaccine; 2017 Jun 27; 35(30):3726-3732. PubMed ID: 28578824
    [Abstract] [Full Text] [Related]

  • 20. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
    Rouhani M, Zakeri S, Mehrizi AA, Djadid ND.
    Malar J; 2015 Feb 05; 14():58. PubMed ID: 25652589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.